These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3900166)

  • 1. Moxalactam in nosocomial infections with Serratia marcescens.
    Mall T; Follath F; Salfinger M; Ritz R; Reber H
    Intensive Care Med; 1985; 11(4):179-83. PubMed ID: 3900166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.
    Markowitz SM; Sibilla DJ
    Antimicrob Agents Chemother; 1980 Nov; 18(5):651-5. PubMed ID: 7004344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.
    Sanders CC; Watanakunakorn C
    J Infect Dis; 1986 Mar; 153(3):617-9. PubMed ID: 3512733
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nosocomial infections caused by multi-resistant Serratia marcescens at a university clinic--clinical aspects and drug resistance].
    Halle E; Grauel EL; Klare I; Bollmann R; Buchholz P; Scholowska-Köhler W; Witte W; Göldner B; Baumann B
    Padiatr Grenzgeb; 1989; 28(5):299-309. PubMed ID: 2695885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxalactam for treatment of nosocomial infections.
    Winston DJ; Kurtz TO; Young LS; Busuttil RW
    Rev Infect Dis; 1982; 4 Suppl():S650-S655. PubMed ID: 6218578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New inactivating enzyme of aminoglycoside antibiotics produced by genes on R-plasmid of Serratia spp. and nosocomial infection].
    Hayashi I; Onuma K; Morohoshi T
    Kansenshogaku Zasshi; 1991 Apr; 65(4):465-71. PubMed ID: 2071963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
    Kawakami Y; Okimura Y; Horiuchi N; Kanai M
    Jpn J Antibiot; 1982 Sep; 35(9):2314-7. PubMed ID: 6292543
    [No Abstract]   [Full Text] [Related]  

  • 9. Unusual aminoglycoside susceptibility pattern and mechanisms of resistance of Serratia marcescens strains from Italy.
    Kettner M; Krcméry V; Bonini P; Cichero P; Ossi C; Grazioli V
    Infection; 1991; 19(4):253. PubMed ID: 1917041
    [No Abstract]   [Full Text] [Related]  

  • 10. Serratia marcescens.
    Hejazi A; Falkiner FR
    J Med Microbiol; 1997 Nov; 46(11):903-12. PubMed ID: 9368530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serratia marcescens nosocomial infections of the urinary tract associated with urine measuring containers and urinometers.
    Rutala WA; Kennedy VA; Loflin HB; Sarubbi FA
    Am J Med; 1981 Mar; 70(3):659-63. PubMed ID: 7011020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy.
    Craven PC; Jorgensen JH; Kaspar RL; Drutz DJ
    Am J Med; 1977 Jun; 62(6):902-10. PubMed ID: 326046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance.
    Shih HI; Lee HC; Lee NY; Chang CM; Wu CJ; Wang LR; Ko NY; Ko WC
    J Microbiol Immunol Infect; 2005 Oct; 38(5):350-7. PubMed ID: 16211144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin treatment associated with later nosocomial gentamicin-resistant Serratia marcescens infections.
    Graham DR; Clegg HW; Anderson RL; Chelgren GA; Mostow SR; Dixon RE
    Infect Control; 1981; 2(1):31-7. PubMed ID: 7012063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient factors contributing to the emergence of gentamicin-resistant Serratia marcescens.
    Yu VL; Oakes CA; Axnick KJ; Merigan TC
    Am J Med; 1979 Mar; 66(3):468-72. PubMed ID: 373434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serratia marcescens bacteremia: clinical features and antimicrobial susceptibilities of the isolates.
    Yu WL; Lin CW; Wang DY
    J Microbiol Immunol Infect; 1998 Sep; 31(3):171-9. PubMed ID: 10496154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens.
    Goldstein FW; Gutmann L; Williamson R; Collatz E; Acar JF
    Ann Microbiol (Paris); 1983; 134A(3):329-37. PubMed ID: 6357025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycoside resistance patterns of Serratia marcescens strains of clinical origin.
    Coria-Jiménez R; Ortiz-Torres C
    Epidemiol Infect; 1994 Feb; 112(1):125-31. PubMed ID: 8119351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third generation cephalosporins--a panacea for intensive care patients?
    Waldvogel FA
    Intensive Care Med; 1985; 11(4):184-5. PubMed ID: 4044993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.